Compare Pacific Gas & Electric Co. Common Stock (PCG) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance

PCG trades at $13.33, up 1.29% with a bullish technical signal despite mixed momentum indicators. The stock shows strong fundamentals with a P/E of 9.59 and net income margin of 12.25%, supported by recent earnings beats. Recent news highlights PG&E's proactive wildfire safety measures and strategic initiatives, including a 10-year undergrounding plan to mitigate risks. Analyst consensus remains positive with a $18.22 price target, though technical indicators show some overbought conditions.

PCG presents a value opportunity with attractive valuation metrics and improving profitability, but faces significant wildfire-related risks and regulatory uncertainty. The stock's upside potential depends on successful execution of safety initiatives and favorable regulatory outcomes, making it suitable for risk-tolerant investors seeking utility exposure with growth potential.

Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.

The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.